Abbvie Inc. has prepared and tested new antibody-drug conjugates comprising an antibody targeting seizure protein 6 homolog (SEZ6) covalently linked to DNA topoisomerase I inhibitors through a linker.
Asgard Therapeutics AB has announced a €30 million (US$32.7 million) series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology.
Seven years since the first approval of two chimeric antigen receptor T-cell therapies for hematological cancers, U.S. and Singapore-based Immunoscape Pte Ltd. is looking to develop novel T-cell receptor (TCR) therapeutics for solid tumors.